Development of differentiation modulators and targeted agents for treating neuroblastoma

Zegao Jin; Yang Lu; Yizhe Wu; Jinxin Che; Xiaowu Dong

doi:10.1016/j.ejmech.2020.112818

Development of differentiation modulators and targeted agents for treating neuroblastoma

Eur J Med Chem. 2020 Dec 1:207:112818. doi: 10.1016/j.ejmech.2020.112818. Epub 2020 Sep 8.

Authors

Zegao Jin¹, Yang Lu¹, Yizhe Wu¹, Jinxin Che², Xiaowu Dong³

Affiliations

¹ Hangzhou Institute of Innovative Medicine, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310058, PR China.
² Hangzhou Institute of Innovative Medicine, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310058, PR China. Electronic address: [email protected].
³ Hangzhou Institute of Innovative Medicine, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310058, PR China; Innovation Institute for Artificial Intelligence in Medicine, Zhejiang University, Hangzhou, 310058, PR China; Cancer Center of Zhejiang University, Hangzhou, 310058, PR China. Electronic address: [email protected].

PMID: 32937281
DOI: 10.1016/j.ejmech.2020.112818

Abstract

Neuroblastoma (NB) is one of the most common pediatric malignancies. Easy metastasis, poor prognosis, and a high degree of heterogeneity of NB hinder its successful treatment. Several different therapeutic strategies have been developed to overcome these problems, including differentiation and targeted therapy. In this review, we summarize the recent development of differentiation modulators and targeted agents for treating NB. Several promising targets of NB were also discussed.

Keywords: Differentiation therapy; Neuroblastoma; Targeted therapy.

Publication types

Review

MeSH terms

Animals
Antineoplastic Agents / pharmacology*
Antineoplastic Agents / therapeutic use
Cell Differentiation / drug effects*
Drug Discovery*
Humans
Molecular Targeted Therapy*
Neuroblastoma / drug therapy*
Neuroblastoma / pathology*

Substances

Antineoplastic Agents